Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis.
Cytochrome P450 2E1 (CYP2E1) plays an important role in the pathogenesis of nonalcoholic steatohepatitis (NASH) in animal models, but its role in the pathogenesis of human NASH is unclear. Therefore, we measured hepatic CYP2E1 activity and its correlates in a cohort of nondiabetic patients with NASH (NDN) and controls to explore its role in the pathogenesis of human NASH. Hepatic CYP2E1 activity was assessed using the oral clearance (CL(PO)) of chlorzoxazone (CHZ) in 20 NDN and 17 age, gender, and body mass index (BMI)-matched controls. The relationship between hepatic CYP2E1 activity and demographic and anthropometric variables; fasting levels of insulin, glucose, lipids, and beta-OH butyrate; insulin resistance; and nocturnal hypoxemia was assessed. Furthermore, expression of CYP2E1 in the peripheral lymphocytes was assessed using reverse transcription-polymerase chain reaction (RT-PCR). The CL(PO) of CHZ was significantly (P =.03) greater in NDN (41 +/- 12 L/h) compared with controls (33 +/- 16 L/h). Lymphocyte CYP2E1 messenger RNA was significantly higher in NDN compared with controls (11.5 x 10(3) +/- 10 x 10(3) vs. 2.6 x 10(3) +/- 1.2 x 10(3) molecules/microg total RNA, respectively, P <.001). On univariate analysis, BMI, respiratory quotient, high-density lipoprotein, triglycerides, insulin, insulin resistance, hypoxemia, and beta-OH butyrate significantly correlated with hepatic CYP2E1 activity. However, on stepwise regression analysis, only nocturnal hypoxemia (r = 0.50, P =.009) and beta-OH butyrate (r = 0.37, P =.04) were independent predictors of hepatic CYP2E1 activity. In conclusion, hepatic CYP2E1 activity and lymphocyte CYP2E1 expression are enhanced in NDN. The significant correlations noted between CYP2E1 and hypoxemia and beta-OH butyrate suggest that these factors play a role in increased CYP2E1 activity that is seen in patients with NASH.
Chalasani
Naga
N
Division of Gastroenterology/Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA. nchalasa@iupui.edu
Gorski
J Christopher
JC
Asghar
Maleeha S
MS
Asghar
Ali
A
Foresman
Brian
B
Hall
Stephen D
SD
Crabb
David W
DW
D020155:3-Hydroxybutyric Acid / Q000097:blood; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002753:Chlorzoxazone / Q000493:pharmacokinetics; D008076:Cholesterol, HDL / Q000097:blood; D019392:Cytochrome P-450 CYP2E1 / Q000235:genetics / Q000378:metabolism*; D005234:Fatty Liver / Q000201:enzymology* / Q000473:pathology; D005260:Female; D006521:Hepatitis, Chronic / Q000201:enzymology* / Q000473:pathology; D006801:Humans; D000860:Hypoxia; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008099:Liver / Q000201:enzymology* / Q000473:pathology; D008214:Lymphocytes / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000097:blood; D012044:Regression Analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D008076:Cholesterol, HDL; D007328:Insulin; D008055:Lipids; D012333:RNA, Messenger; D014280:Triglycerides; D019392:Cytochrome P-450 CYP2E1; D002753:Chlorzoxazone; D020155:3-Hydroxybutyric Acid